These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 16159685

  • 1. Induction of balanced immunity in BALB/c mice by vaccination with a recombinant fusion protein containing a respiratory syncytial virus G protein fragment and a CTL epitope.
    Zeng RH, Gong W, Fan CF, Wang YF, Mei XG.
    Vaccine; 2006 Feb 13; 24(7):941-7. PubMed ID: 16159685
    [Abstract] [Full Text] [Related]

  • 2. Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2.
    Zeng R, Qi X, Gong W, Mei X, Wei L, Ma C, Yin X.
    Vaccine; 2007 Oct 16; 25(42):7422-8. PubMed ID: 17850930
    [Abstract] [Full Text] [Related]

  • 3. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu Y, He J, Zheng X, Wu Q, Zhang M, Wang X, Wang Y, Xie C, Tang Q, Wei W, Wang M, Song J, Qu J, Zhang Y, Wang X, Hong T.
    Biochem Biophys Res Commun; 2009 Apr 17; 381(4):528-32. PubMed ID: 19233131
    [Abstract] [Full Text] [Related]

  • 4. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X, Sambhara S, Li CX, Ettorre L, Switzer I, Cates G, James O, Parrington M, Oomen R, Du RP, Klein M.
    Virology; 2000 Mar 30; 269(1):54-65. PubMed ID: 10725198
    [Abstract] [Full Text] [Related]

  • 5. [Plasmid construction, expression, immunogenicity and protective efficacy of recombinant protein candidate vaccine of respiratory syncytial virus].
    Zeng RH, Gong W, Fang XP, Zhang ZY, Mei XG.
    Sheng Wu Gong Cheng Xue Bao; 2005 Jul 30; 21(4):534-9. PubMed ID: 16176088
    [Abstract] [Full Text] [Related]

  • 6. Co-immunization of BALB/c mice with recombinant immunogens containing G protein fragment and chimeric CTL epitope of respiratory syncytial virus induces enhanced cellular immunity and high level of antibody response.
    Fan CF, Mei XG.
    Vaccine; 2005 Aug 15; 23(35):4453-61. PubMed ID: 15935522
    [Abstract] [Full Text] [Related]

  • 7. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.
    Power UF, Plotnicky-Gilquin H, Huss T, Robert A, Trudel M, Ståhl S, Uhlén M, Nguyen TN, Binz H.
    Virology; 1997 Apr 14; 230(2):155-66. PubMed ID: 9143271
    [Abstract] [Full Text] [Related]

  • 8. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
    Huang Y, Cyr SL, Burt DS, Anderson R.
    J Clin Virol; 2009 Apr 14; 44(4):287-91. PubMed ID: 19233722
    [Abstract] [Full Text] [Related]

  • 9. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
    Elliott MB, Chen T, Terio NB, Chong SY, Abdullah R, Luckay A, Egan MA, Boutilier LA, Melville K, Lerch RA, Long D, Eldridge JH, Parks CL, Udem SA, Hancock GE.
    Vaccine; 2007 Oct 10; 25(41):7132-44. PubMed ID: 17850933
    [Abstract] [Full Text] [Related]

  • 10. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus.
    Mottram PL, Leong D, Crimeen-Irwin B, Gloster S, Xiang SD, Meanger J, Ghildyal R, Vardaxis N, Plebanski M.
    Mol Pharm; 2007 Oct 10; 4(1):73-84. PubMed ID: 17274665
    [Abstract] [Full Text] [Related]

  • 11. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
    Cyr SL, Jones T, Stoica-Popescu I, Brewer A, Chabot S, Lussier M, Burt D, Ward BJ.
    Vaccine; 2007 Jul 20; 25(29):5378-89. PubMed ID: 17561317
    [Abstract] [Full Text] [Related]

  • 12. Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection.
    Kim S, Jang JE, Yu JR, Chang J.
    Vaccine; 2010 May 14; 28(22):3801-8. PubMed ID: 20362203
    [Abstract] [Full Text] [Related]

  • 13. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
    Johnson TR, Graham BS.
    Pediatr Infect Dis J; 2004 Jan 14; 23(1 Suppl):S46-57. PubMed ID: 14730270
    [Abstract] [Full Text] [Related]

  • 14. Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies.
    Voges B, Vallbracht S, Zimmer G, Bossow S, Neubert WJ, Richter K, Hobeika E, Herrler G, Ehl S.
    Cell Immunol; 2007 Jun 14; 247(2):85-94. PubMed ID: 17904538
    [Abstract] [Full Text] [Related]

  • 15. Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus.
    Bukreyev A, Belyakov IM, Prince GA, Yim KC, Harris KK, Berzofsky JA, Collins PL.
    J Virol; 2005 Aug 14; 79(15):9515-26. PubMed ID: 16014914
    [Abstract] [Full Text] [Related]

  • 16. Respiratory syncytial virus subunit vaccine based on a recombinant fusion protein expressed transiently in mammalian cells.
    Nallet S, Amacker M, Westerfeld N, Baldi L, König I, Hacker DL, Zaborosch C, Zurbriggen R, Wurm FM.
    Vaccine; 2009 Oct 30; 27(46):6415-9. PubMed ID: 19559121
    [Abstract] [Full Text] [Related]

  • 17. Reduction of respiratory syncytial virus titer in the lungs of mice after intranasal immunization with a chimeric peptide consisting of a single CTL epitope linked to a fusion peptide.
    Hsu SC, Chargelegue D, Steward MW.
    Virology; 1998 Jan 20; 240(2):376-81. PubMed ID: 9454711
    [Abstract] [Full Text] [Related]

  • 18. RSV recombinant candidate vaccine G1F/M2 with CpG as an adjuvant prevents vaccine-associated lung inflammation, which may be associated with the appropriate types of immune memory in spleens and lungs.
    Li N, Zhang L, Zheng B, Li W, Liu J, Zhang H, Zeng R.
    Hum Vaccin Immunother; 2019 Jan 20; 15(11):2684-2694. PubMed ID: 31021703
    [Abstract] [Full Text] [Related]

  • 19. Fusion of DsbA to the N-terminus of CTL chimeric epitope, F/M2:81-95, of respiratory syncytial virus prolongs protein- and virus-specific CTL responses in Balb/c mice.
    Fan CF, Zeng RH, Sun CY, Mei XG, Wang YF, Liu Y.
    Vaccine; 2005 Apr 22; 23(22):2869-75. PubMed ID: 15780735
    [Abstract] [Full Text] [Related]

  • 20. Identification of an H-2D(b)-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus.
    Rutigliano JA, Rock MT, Johnson AK, Crowe JE, Graham BS.
    Virology; 2005 Jul 05; 337(2):335-43. PubMed ID: 15916793
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.